[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524334":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":11,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"CellSight Technologies, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Advanced non small cell lung cancer (NSCLC) patients undergoing PD-1\u002FPD-L1 directed therapy","EXPERIMENTAL",null,[13],"Drug: [18F]F-AraG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","[18F]F-AraG","Two PET scans",[9],[21],{"name":22,"affiliation":23,"role":24},"Muhammad Furqan, M.D.","Holden Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Amy Mundisev","CONTACT","319-356-1445","amy-mundisev@uiowa.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"University of Iowa Hospitals and Clinics","RECRUITING","Iowa City","Iowa","52246","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-91.53017,41.66113,{"lat":44,"lon":43},[47],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100524334","phase-2-imaging-advanced-nsclc-patients-undergoing-pd-1pd-l1-directed-therapy-using-18f-farag-100524334",false,"NCT06107374","Imaging Advanced NSCLC Patients Undergoing PD-1\u002FPD-L1 Directed Therapy Using [18F]-FARAG","Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1\u002FPD-L1 Directed Therapy","Inclusion Criteria:\n\n1. Histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy for advanced\u002Fmetastatic disease.\n2. Measurable disease.\n3. ECOG performance status of 0, 1 or 2.\n4. Subjects are willing to be followed at the University of Iowa.\n\nExclusion Criteria:\n\n1. Serious comorbidities that in the opinion of the investigator\u002Fsponsor could compromise protocol objectives.\n2. Pregnant women or nursing mothers.\n3. Patients with severe claustrophobia.","ALL","18 Years",{"count":60,"type":61},20,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This pilot study uses \\[18F\\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to quantify the change in \\[18F\\]F AraG PET signal before and while on CkIT therapy and to correlate this change in \\[18F\\]F AraG PET signal with radiographic response.\n\nTo explore these objectives, eligible subjects will undergo pre- and on - CkIT treatment \\[18F\\]F AraG PET\u002FCT scans, and will be followed up for 12 months for assessment of radiographic and clinical outcomes. This study is a single-site, open label, non randomized, single arm pilot trial. Patients and care providers will not be blinded to any part of the study.",[67],"Advanced Non Small Cell Lung Cancer","2024-10-22",{"date":70,"type":71},"2024-10-24","ACTUAL",{"date":73,"type":71},"2023-11-01",{"date":75,"type":61},"2026-03-31",{"name":5,"class":6},1]